<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00960739</url>
  </required_header>
  <id_info>
    <org_study_id>MIITOP-0607</org_study_id>
    <nct_id>NCT00960739</nct_id>
  </id_info>
  <brief_title>Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma</brief_title>
  <acronym>MIITOP</acronym>
  <official_title>Phase II Study of the Association of Iodobenzylguanidine Meta-I131 (I131 MIBG) and Topotecan in the Treatment of Refractory or Relapsed Metastatic Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radioactive drugs, such as iodobenzylguanidine meta-I131, may carry radiation&#xD;
      directly to tumor cells and not harm normal cells. Drugs used in chemotherapy, such as&#xD;
      topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by&#xD;
      killing the cells or by stopping them from dividing. A stem cell transplant may be able to&#xD;
      replace the cells that were destroyed by iodobenzylguanidine meta-i131 and topotecan&#xD;
      hydrochloride.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects of iodobenzylguanidine meta-I131&#xD;
      given together with topotecan hydrochloride and to see how well it works in treating young&#xD;
      patients with refractory or relapsed metastatic neuroblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the antitumor activity of iodobenzylguanidine meta-I131 (^131I-MIBG) and&#xD;
           topotecan in young patients with refractory or relapsed metastatic neuroblastoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the hematological and extra-hematological toxicities of this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      During the 21 days before treatment begins, autologous peripheral blood stem cells (PBSC) are&#xD;
      collected.&#xD;
&#xD;
      Patients receive topotecan hydrochloride IV over 30 minutes daily on days 1-5 and&#xD;
      iodobenzylguanidine meta-^131I IV over 2 hours on day 1. Treatment repeats every 21 days for&#xD;
      2 courses. Patients also undergo total-body irradiation.&#xD;
&#xD;
      On day 10 of the second course, autologous PBSC are reinfused.&#xD;
&#xD;
      After completion of study therapy, patients are followed at 6 and 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Up to 30 days after study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Topotecan / 131-iodine MIBG association</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The topotecan hydrochloride is administered intravenously over five days to dose of 0.7 mg/ m²/day from day 1 to day 5 (first cycle), then from day 21 to day 25 (second cycle). *&#xD;
Iobenguane I 131: 444 MBq / kg of 131-iodine MIBG is administered on day 1 with activity up to 11,100 MBq per injection. *&#xD;
A dosimetry is performed during hospitalization.&#xD;
A second dose of 131-iodine MIBG (maximum 11 100 MBq) is administered to D21 so as to obtain a total body irradiation of 4 Gy. *&#xD;
Autologous hematopoietic stem cell transplantation : Hematopoietic stem cells are reinjected 10 days after the second injection of 131-iodine MIBG.&#xD;
If the dose of total-body irradiation of 4 Gy is reached during the first cycle, the second cycle is canceled.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan hydrochloride</intervention_name>
    <description>The topotecan hydrochloride is administered intravenously over five days to dose of 0.7 mg/ m²/day from day 1 to day 5 (first cycle), then from day 21 to day 25 (second cycle)</description>
    <arm_group_label>Topotecan / 131-iodine MIBG association</arm_group_label>
    <other_name>Topotecan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous hematopoietic stem cell transplantation</intervention_name>
    <description>Hematopoietic stem cells are reinjected 10 days after the second injection of 131-iodine MIBG</description>
    <arm_group_label>Topotecan / 131-iodine MIBG association</arm_group_label>
    <other_name>hematopoietic stem cell transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>iobenguane I 131</intervention_name>
    <description>444 MBq / kg of 131-iodine MIBG is administered on day 1 with activity</description>
    <arm_group_label>Topotecan / 131-iodine MIBG association</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
    <description>the dose of total-body irradiation of 4 Gy is reached during the first cycle, the second cycle is canceled (131-iodine MIBG and Topotecan)</description>
    <arm_group_label>Topotecan / 131-iodine MIBG association</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Histologically confirmed neuroblastoma&#xD;
&#xD;
          -  Metastatic disease that is recurrent or refractory to induction therapy&#xD;
&#xD;
          -  Primary or metastatic tumor target with MIBG fixation (tumor/soft tissue) &gt; 2&#xD;
&#xD;
          -  Autologous bone marrow or peripheral blood stem cells must be available&#xD;
&#xD;
          -  WHO performance status (PS) 0-1 OR Lansky PS 70-100%&#xD;
&#xD;
          -  Life expectancy &gt; 2 months&#xD;
&#xD;
          -  ANC ≥ 1,000/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Creatinine clearance normal for age&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior hypersensitivity to topotecan or its excipients&#xD;
&#xD;
          -  No toxicity to other organs ≥ NCI-CTCAE v3.0 grade 2&#xD;
&#xD;
          -  No other debilitating disease&#xD;
&#xD;
          -  No HIV positivity&#xD;
&#xD;
          -  More than 30 days since prior external-beam radiation (6 weeks if cranio-spinal,&#xD;
             abdominal, or pulmonary)&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy (6 weeks for mitomycin C or nitrosoureas)&#xD;
&#xD;
          -  No other contraindicated biologic therapy that cannot be discontinued for ≥ 4 courses&#xD;
             during MIBG therapy&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Pregnancy or breastfeeding women&#xD;
&#xD;
          -  HIV positive&#xD;
&#xD;
          -  Participation to another phase I,II or III clinical trial&#xD;
&#xD;
          -  Other invalidating pathology&#xD;
&#xD;
          -  Concomitant treatment interfering with MIBG&#xD;
&#xD;
          -  Hypersensibility to Topotecan&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Sophie Defachelles, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital des Enfants</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>August 16, 2009</study_first_submitted>
  <study_first_submitted_qc>August 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2009</study_first_posted>
  <last_update_submitted>August 5, 2016</last_update_submitted>
  <last_update_submitted_qc>August 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>localized unresectable neuroblastoma</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>stage 4S neuroblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>3-Iodobenzylguanidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

